Topiramate

This article is a stub.

Topiramate is generally better tolerated than valproate for migraine prophylaxis. According to a comparative study, topiramate at 50 mg/day showed fewer side effects compared to valproate at 400 mg/day, with significant reductions in headache severity and fewer adverse events. The American Academy of Neurology and the American Headache Society also support the use of topiramate as a first-line option for migraine prevention, noting its favorable side effect profile compared to valproate.^[1]^[2]

Resources

Topiramate in Migraine - Silberstein 2016.pdf - 266 KB (f)

References

↑ Afshari, Dariush; Rafizadeh, Shabnam; Rezaei, Mansour (2012-02). "A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis". The International Journal of Neuroscience. 122 (2): 60–68. doi:10.3109/00207454.2011.626908. ISSN 1563-5279. PMID 21950578. Check date values in: |date= (help)
↑ Silberstein, S. D.; Holland, S.; Freitag, F.; Dodick, D. W.; Argoff, C.; Ashman, E.; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society (2012-04-24). "Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society". Neurology. 78 (17): 1337–1345. doi:10.1212/WNL.0b013e3182535d20. ISSN 1526-632X. PMC 3335452. PMID 22529202.

[1] Afshari, Dariush; Rafizadeh, Shabnam; Rezaei, Mansour (2012-02). "A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis". The International Journal of Neuroscience. 122 (2): 60–68. doi:10.3109/00207454.2011.626908. ISSN 1563-5279. PMID 21950578. Check date values in: |date= (help)

[2] Silberstein, S. D.; Holland, S.; Freitag, F.; Dodick, D. W.; Argoff, C.; Ashman, E.; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society (2012-04-24). "Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society". Neurology. 78 (17): 1337–1345. doi:10.1212/WNL.0b013e3182535d20. ISSN 1526-632X. PMC 3335452. PMID 22529202.

[1]

[2]